BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021;6:201. [PMID: 34054126 DOI: 10.1038/s41392-021-00572-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jha NK, Arfin S, Jha SK, Kar R, Dey A, Gundamaraju R, Ashraf GM, Gupta PK, Dhanasekaran S, Abomughaid MM, Das SS, Singh SK, Dua K, Roychoudhury S, Kumar D, Ruokolainen J, Ojha S, Kesari KK. Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling. Semin Cancer Biol 2022:S1044-579X(22)00049-9. [PMID: 35218902 DOI: 10.1016/j.semcancer.2022.02.022] [Reference Citation Analysis]
2 Tong S, Darwish S, Ariani HHN, Lozada KA, Salehi D, Cinelli MA, Silverman RB, Kaur K, Yang S. A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022;14:1036. [DOI: 10.3390/pharmaceutics14051036] [Reference Citation Analysis]
3 Gutierrez C, Vilas CK, Wu CJ, Al’khafaji AM. Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer. Front Immunol 2022;13:859032. [DOI: 10.3389/fimmu.2022.859032] [Reference Citation Analysis]
4 Beck H, Härter M, Haß B, Schmeck C, Baerfacker L. Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory. Drug Discov Today 2022:S1359-6446(22)00073-3. [PMID: 35202802 DOI: 10.1016/j.drudis.2022.02.015] [Reference Citation Analysis]
5 Knighton LE, Nitika, Wani TH, Truman AW. Chemogenomic and bioinformatic profiling of ERdj paralogs underpins their unique roles in cancer. Cell Stress Chaperones 2022. [PMID: 35129801 DOI: 10.1007/s12192-022-01256-2] [Reference Citation Analysis]
6 Noorbakhsh N, Hayatmoghadam B, Jamali M, Golmohammadi M, Kavianpour M. The Hippo signaling pathway in leukemia: function, interaction, and carcinogenesis. Cancer Cell Int 2021;21:705. [PMID: 34953494 DOI: 10.1186/s12935-021-02408-7] [Reference Citation Analysis]
7 Cristina Mendonça Nogueira T, Vinicius Nora de Souza M. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications. Bioorg Med Chem 2021;46:116340. [PMID: 34416511 DOI: 10.1016/j.bmc.2021.116340] [Reference Citation Analysis]
8 Sittihan S, Sopha P, Ruchirawat S. Synthesis and Anticancer Activity of Pentafluorobenzenesulfonamide Derivatives as Caspase-Dependent Apoptosis-Inducing Agents. ChemMedChem 2021. [PMID: 34784449 DOI: 10.1002/cmdc.202100637] [Reference Citation Analysis]
9 Pastorino F, Brignole C. Editorial of the Special Issue “Targeted Therapies for Cancer”. Biomedicines 2022;10:1114. [DOI: 10.3390/biomedicines10051114] [Reference Citation Analysis]
10 Iannello A, Deaglio S, Vaisitti T. Novel Approaches for the Treatment of Patients with Richter's Syndrome. Curr Treat Options Oncol 2022. [PMID: 35294723 DOI: 10.1007/s11864-022-00973-1] [Reference Citation Analysis]
11 Schwartz-Duval AS, Sokolov KV. Prospecting Cellular Gold Nanoparticle Biomineralization as a Viable Alternative to Prefabricated Gold Nanoparticles. Adv Sci (Weinh) 2022;:e2105957. [PMID: 35508715 DOI: 10.1002/advs.202105957] [Reference Citation Analysis]
12 Christou E, Pearson JR, Beltrán AM, Fernández-afonso Y, Gutiérrez L, de la Fuente JM, Gámez F, García-martín ML, Caro C. Iron–Gold Nanoflowers: A Promising Tool for Multimodal Imaging and Hyperthermia Therapy. Pharmaceutics 2022;14:636. [DOI: 10.3390/pharmaceutics14030636] [Reference Citation Analysis]
13 Azad I, Jat JL, Yadav AK, Saha S, Akhter Y. Evaluation of anticancer activity of N H/N-Me Aziridine derivatives as a potential poly (ADP-ribose) polymerase 1 inhibitor. Journal of Molecular Structure 2022;1258:132689. [DOI: 10.1016/j.molstruc.2022.132689] [Reference Citation Analysis]
14 Xie H, Liu J, Alem Glison DM, Fleming JB. The clinical advances of proteolysis targeting chimeras in oncology. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00061] [Reference Citation Analysis]
15 Xiao Y, Chen Y, Peng A, Dong J. The phosphatase CTDSPL2 is phosphorylated in mitosis and a target for restraining tumor growth and motility in pancreatic cancer. Cancer Lett 2022;526:53-65. [PMID: 34813892 DOI: 10.1016/j.canlet.2021.11.018] [Reference Citation Analysis]
16 Markowicz J, Uram Ł, Wołowiec S, Rode W. Biotin Transport-Targeting Polysaccharide-Modified PAMAM G3 Dendrimer as System Delivering α-Mangostin into Cancer Cells and C. elegans Worms. Int J Mol Sci 2021;22:12925. [PMID: 34884739 DOI: 10.3390/ijms222312925] [Reference Citation Analysis]
17 Li Y, Wei L, Meinsohn MC, Suliman R, Chauvin M, Berstler J, Hartland K, Jensen MM, Sicher NA, Nagykery N, Donahoe PK, Pepin D. A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives. Proc Natl Acad Sci U S A 2022;119:e2122512119. [PMID: 35380904 DOI: 10.1073/pnas.2122512119] [Reference Citation Analysis]
18 Sun H, Zhang L, Sui B, Li Y, Yan J, Wang P, Wang Y, Liu S. The Effect of Terpenoid Natural Chinese Medicine Molecular Compound on Lung Cancer Treatment. Evid Based Complement Alternat Med 2021;2021:3730963. [PMID: 34956377 DOI: 10.1155/2021/3730963] [Reference Citation Analysis]
19 Bibby G, Krasniqi B, Reddy I, Sekar D, Ross K. Capturing the RNA castle: Exploiting MicroRNA inhibition for wound healing. FEBS J 2021. [PMID: 34403569 DOI: 10.1111/febs.16160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Porębska N, Knapik A, Poźniak M, Krzyścik MA, Zakrzewska M, Otlewski J, Opaliński Ł. Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers. Biomacromolecules 2021;22:5349-62. [PMID: 34855396 DOI: 10.1021/acs.biomac.1c01280] [Reference Citation Analysis]
21 Shukla S, Fletcher S, Chauhan J, Chalfant V, Riveros C, Mackeyev Y, Singh PK, Krishnan S, Osumi T, Balaji KC. 3JC48-3 (methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth. Cancer Gene Ther 2022. [PMID: 35440696 DOI: 10.1038/s41417-022-00455-4] [Reference Citation Analysis]
22 Mahmoud MA, El-Bana MA, Morsy SM, Badawy EA, Farrag AE, Badawy AM, Abdel-Wahhab MA, El-Dosoky MA. Synthesis and characterization of berberine-loaded chitosan nanoparticles for the protection of urethane-induced lung cancer. Int J Pharm 2022;618:121652. [PMID: 35278602 DOI: 10.1016/j.ijpharm.2022.121652] [Reference Citation Analysis]
23 Zheng J, Zhang W, Li L, He Y, Wei Y, Dang Y, Nie S, Guo Z. Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review. Front Chem 2022;10:860985. [DOI: 10.3389/fchem.2022.860985] [Reference Citation Analysis]
24 Dyshlovoy SA. Recent Updates on Marine Cancer-Preventive Compounds. Mar Drugs 2021;19:558. [PMID: 34677457 DOI: 10.3390/md19100558] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Tobias J, Steinberger P, Drinić M, Wiedermann U. Emerging targets for anticancer vaccination: PD-1. ESMO Open 2021;6:100278. [PMID: 34649221 DOI: 10.1016/j.esmoop.2021.100278] [Reference Citation Analysis]
26 Othman IMM, Alamshany ZM, Tashkandi NY, Gad-elkareem MAM, Abd El-karim SS, Nossier ES. Synthesis and biological evaluation of new derivatives of thieno-thiazole and dihydrothiazolo-thiazole scaffolds integrated with a pyrazoline nucleus as anticancer and multi-targeting kinase inhibitors. RSC Adv 2021;12:561-77. [DOI: 10.1039/d1ra08055e] [Reference Citation Analysis]
27 Sheffield BS, Beharry A, Diep J, Perdrizet K, Iafolla MAJ, Raskin W, Dudani S, Brett MA, Starova B, Olsen B, Cheema PK. Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care. Current Oncology 2022;29:1326-34. [DOI: 10.3390/curroncol29030113] [Reference Citation Analysis]
28 Sharma P, Jhawat V, Mathur P, Dutt R. Innovation in cancer therapeutics and regulatory perspectives. Med Oncol 2022;39:76. [PMID: 35195787 DOI: 10.1007/s12032-022-01677-0] [Reference Citation Analysis]
29 Tanaka R, Sato J, Ishikawa H, Sato T, Shino M, Ohde Y, Sato T, Mori K, Notsu A, Ohnami S, Mizuguchi M, Nagashima T, Yamaguchi K. Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study. Medicine (Baltimore) 2021;100:e27565. [PMID: 34871222 DOI: 10.1097/MD.0000000000027565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Katona G, Sabir F, Sipos B, Naveed M, Schelz Z, Zupkó I, Csóka I. Development of Lomustine and n-Propyl Gallate Co-Encapsulated Liposomes for Targeting Glioblastoma Multiforme via Intranasal Administration. Pharmaceutics 2022;14:631. [DOI: 10.3390/pharmaceutics14030631] [Reference Citation Analysis]
31 Han Z, Zhou D, Wang J, Jiang B, Liu X. Reflections on drug resistance to KRASG12C inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment. Biochim Biophys Acta Rev Cancer 2022;:188677. [PMID: 35033622 DOI: 10.1016/j.bbcan.2022.188677] [Reference Citation Analysis]
32 Goel Y, Fouda R, Gupta K. Endoplasmic Reticulum Stress in Chemotherapy-Induced Peripheral Neuropathy: Emerging Role of Phytochemicals. Antioxidants 2022;11:265. [DOI: 10.3390/antiox11020265] [Reference Citation Analysis]
33 Imoto H, Yamashiro S, Okada M. A text-based computational framework for patient -specific modeling for classification of cancers. iScience 2022. [DOI: 10.1016/j.isci.2022.103944] [Reference Citation Analysis]
34 Milton AV, Konrad DB. Epithelial-mesenchymal transition and H2O2 signaling - a driver of disease progression and a vulnerability in cancers. Biol Chem 2022. [PMID: 35032422 DOI: 10.1515/hsz-2021-0341] [Reference Citation Analysis]
35 Mongre RK, Mishra CB, Shukla AK, Prakash A, Jung S, Ashraf-Uz-Zaman M, Lee MS. Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure? Int J Mol Sci 2021;22:11659. [PMID: 34769090 DOI: 10.3390/ijms222111659] [Reference Citation Analysis]
36 Amariucai-mantu D, Antoci V, Sardaru MC, Al Matarneh CM, Mangalagiu I, Danac R. Fused pyrrolo-pyridines and pyrrolo-(iso)quinoline as anticancer agents. Physical Sciences Reviews 2022;0. [DOI: 10.1515/psr-2021-0030] [Reference Citation Analysis]
37 Bussies PL, Richards EG, Rotz SJ, Falcone T. Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction. Reprod Biomed Online 2021:S1472-6483(21)00434-X. [PMID: 34674940 DOI: 10.1016/j.rbmo.2021.09.004] [Reference Citation Analysis]
38 Stefanska B, Tucker SJ, MacEwan DJ. Themed issue: 'New avenues in cancer prevention and treatment'. Br J Pharmacol 2022. [PMID: 35146753 DOI: 10.1111/bph.15715] [Reference Citation Analysis]
39 Helm A, Fournier C, Durante M. Particle radiotherapy and molecular therapies: mechanisms and strategies towards clinical applications. Expert Rev Mol Med 2022;24:e8. [PMID: 35101155 DOI: 10.1017/erm.2022.2] [Reference Citation Analysis]
40 Nagy KS, Toth K, Pallinger E, Takacs A, Kohidai L, Jedlovszky-Hajdu A, Mathe D, Kovacs N, Veres DS, Szigeti K, Molnar K, Krisch E, Puskas JE. Folate-Targeted Monodisperse PEG-Based Conjugates Made by Chemo-Enzymatic Methods for Cancer Diagnosis and Treatment. Int J Mol Sci 2021;22:10347. [PMID: 34638688 DOI: 10.3390/ijms221910347] [Reference Citation Analysis]
41 Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol 2022;12:819128. [DOI: 10.3389/fonc.2022.819128] [Reference Citation Analysis]
42 Pal D, Song IH, Dashrath Warkad S, Song KS, Seong Yeom G, Saha S, Shinde PB, Balasaheb Nimse S. Indazole-based microtubule-targeting agents as potential candidates for anticancer drugs discovery. Bioorg Chem 2022;122:105735. [PMID: 35298962 DOI: 10.1016/j.bioorg.2022.105735] [Reference Citation Analysis]
43 Wang B, Cai H, Waterhouse GIN, Qu X, Yang B, Lu S. Carbon Dots in Bioimaging, Biosensing and Therapeutics: A Comprehensive Review. Small Science. [DOI: 10.1002/smsc.202200012] [Reference Citation Analysis]
44 Michalczyk K, Cymbaluk-Płoska A. Metalloproteinases in Endometrial Cancer-Are They Worth Measuring? Int J Mol Sci 2021;22:12472. [PMID: 34830354 DOI: 10.3390/ijms222212472] [Reference Citation Analysis]
45 Guo F, Zhang Y, Dong W, Guan Y, Shang D. Effect of hydrophobicity on distinct anticancer mechanism of antimicrobial peptide chensinin-1b and its lipoanalog PA-C1b in breast cancer cells. Int J Biochem Cell Biol 2022;143:106156. [PMID: 34999227 DOI: 10.1016/j.biocel.2022.106156] [Reference Citation Analysis]
46 Frankman ZD, Jiang L, Schroeder JA, Zohar Y. Application of Microfluidic Systems for Breast Cancer Research. Micromachines 2022;13:152. [DOI: 10.3390/mi13020152] [Reference Citation Analysis]
47 Pawelczak P, Fedoruk-wyszomirska A, Wyszko E. Antiaging Effect of 4-N-Furfurylcytosine in Yeast Model Manifests through Enhancement of Mitochondrial Activity and ROS Reduction. Antioxidants 2022;11:850. [DOI: 10.3390/antiox11050850] [Reference Citation Analysis]
48 Delinois LJ, De León-vélez O, Vázquez-medina A, Vélez-cabrera A, Marrero-sánchez A, Nieves-escobar C, Alfonso-cano D, Caraballo-rodríguez D, Rodriguez-ortiz J, Acosta-mercado J, Benjamín-rivera JA, González-gonzález K, Fernández-adorno K, Santiago-pagán L, Delgado-vergara R, Torres-ávila X, Maser-figueroa A, Grajales-avilés G, Méndez GIM, Santiago-pagán J, Nieves-santiago M, Álvarez-carrillo V, Griebenow K, Tinoco AD. Cytochrome c: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug. Inorganics 2021;9:83. [DOI: 10.3390/inorganics9110083] [Reference Citation Analysis]
49 Montoya S, Soong D, Nguyen N, Affer M, Munamarty SP, Taylor J. Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines 2021;9:1591. [PMID: 34829820 DOI: 10.3390/biomedicines9111591] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Sharma M, Bakshi AK, Mittapelly N, Gautam S, Marwaha D, Rai N, Singh N, Tiwari P, Aggarwal N, Kumar A, Mishra PR. Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.04.007] [Reference Citation Analysis]
51 Adeniyi O, Hwang M, Sun J, Schuck RN. Premarket assessment of molecular alterations in drug targets: a case study of 2020 drug approvals. Pharmacogenomics 2022. [PMID: 35440173 DOI: 10.2217/pgs-2022-0004] [Reference Citation Analysis]
52 Liu Y, Chen Y, Fei W, Zheng C, Zheng Y, Tang M, Qian Y, Zhang X, Zhao M, Zhang M, Wang F. Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic. Front Bioeng Biotechnol 2021;9:733792. [PMID: 34557478 DOI: 10.3389/fbioe.2021.733792] [Reference Citation Analysis]
53 Elsherbeny MH, Elkamhawy A, Nada H, Abdellattif MH, Lee K, Roh EJ. Development of New Meridianin/Leucettine-Derived Hybrid Small Molecules as Nanomolar Multi-Kinase Inhibitors with Antitumor Activity. Biomedicines 2021;9:1131. [PMID: 34572319 DOI: 10.3390/biomedicines9091131] [Reference Citation Analysis]
54 Dhar B, Kumar Gupta P, Yildirim A. Dynamical behaviour of a tumor-immune model focusing on the dosage of targeted chemotherapeutic drug. International Journal of Computer Mathematics. [DOI: 10.1080/00207160.2022.2074789] [Reference Citation Analysis]
55 Cho H, Shim MK, Yang S, Song S, Moon Y, Kim J, Byun Y, Ahn CH, Kim K. Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy. Pharmaceutics 2021;14:83. [PMID: 35056979 DOI: 10.3390/pharmaceutics14010083] [Reference Citation Analysis]